Chicago-based OrisDX, a salivary diagnostics company, has launched a saliva DNA test for oral cancer.
Oro Lesion is the first noninvasive test for oral cavity squamous cell carcinoma that analyzes DNA from a saliva-based sample. The platform has been proven to have 94% sensitivity, 98% specificity, a positive predictive value of 96% and a negative predictive value of 97%, according to a Nov. 16 news release from the company.
The test is available as a Laboratory Developed Test regulated under the Centers for Medicare and Medicaid Services Clinical Laboratory Improvement Amendments certification and the College of American Pathologists accreditation process.
About 1.6 million to 4.9 million adults over the age of 18 are seen by a dentist with an oral lesion that may be cancerous. If detected earlier, the lesion can be removed, with survival as high as 90%, the release said.
In June 2025, OrisDX raised $4 million to support the launch of the platform.
